Cognito Therapeutics Drops 'Dementia' Terminology in Language Shift
Event summary
- Cognito Therapeutics partners with the Initiative to Change the 'D-Word' to eliminate use of 'dementia' in all communications.
- Company commits to updating terminology across scientific materials, patient resources, and clinical study communications.
- Christian Howell, CEO of Cognito, states the move aims to reduce stigma and encourage earlier engagement with clinicians.
- Initiative's Language Guide is leveraged to adopt clearer, non-stigmatizing terminology aligned with contemporary neuroscience.
The big picture
Cognito Therapeutics' move aligns with broader industry trends toward patient-centered communication and stigma reduction in neurodegenerative disease treatment. The shift in terminology could influence how patients and clinicians approach cognitive impairment, potentially accelerating diagnosis and treatment. This partnership underscores the growing importance of language in shaping healthcare outcomes and industry standards.
What we're watching
- Language Impact
- How the elimination of 'dementia' terminology will affect patient engagement and early detection rates.
- Industry Adoption
- Whether other neurotechnology companies will follow Cognito's lead in adopting more precise, patient-centered language.
- Regulatory Alignment
- The pace at which regulatory bodies and clinical guidelines will adapt to the new terminology standards.
Related topics